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Abstract
BACKGROUND/AIMS: While probiotic bacteria are successfully used in the treatment of ulcerative
colitis, the effect of commercially available probiotic products is still controversial. Here, we study
whether the number of living probiotic bacteria in yoghurts is altered by an interruption of the cold
chain.
METHODS: Three commonly available probiotic yoghurts were kept at 4°C or put at room temperature
(RT) for 6 h or 24 h. An aliquot of each yoghurt was applied on Man-Rogosa-Sharpe agar and incubated
at 37°C for 48 h. Colony forming units (CFU) were counted by microscopy.
RESULTS: The first yoghurt, containing Lactobacillus johnsonii, showed a significant decrease in CFU
after 6 h of storage at RT, which was further pronounced after 24 h. The number of CFU of the second
yoghurt, containing Lactobacillus GG, was also decreased after 6 h and further diminished after 24 h at
RT. From the third yoghurt, containing Lactobacillus acidophilus, only 53.8% of the CFU remained
after 6 h at RT; after 24 h, only about one fourth of the CFU were found.
CONCLUSIONS: Our data demonstrate that the number of living probiotic bacteria in yoghurt products
decreases dramatically after exposure to RT. This represents an important information for consumers of
such products.
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Abstract 
Background/Aims: While probiotic bacteria are successfully used in the treatment of 
ulcerative colitis, the effect of commercially available probiotic products is still controversial. Here, 
we study whether the number of living probiotic bacteria in yoghurts is altered by an interruption of 
the cold chain. 
Methods: Three commonly available probiotic yoghurts were kept on 4°C or put at room temperature 
(RT) for 6 h or 24 h. An aliquot of each yoghurt was applied on MRS agar and incubated at 37°C for 
48 h. Colony forming units (CFU) were counted by microscopy. 
Results: The first yoghurt, containing Lactobacillus johnsonii, showed a significant decrease in CFU 
after 6 h of storage at RT, which was further pronounced after 24 h. The number of CFU of the second 
yoghurt, containing Lactobacillus GG, was also decreased by 6 h and further diminished by 24 h at 
RT. From the third yoghurt, containing Lactobacillus acidophilus, only 53.8% CFU remained after 6 h 
at RT and after 24 h, just about one fourth CFU were found.   
Conclusions: Our data demonstrate that the number of living probiotic bacteria in yoghurt products 
decreases dramatically after exposure to RT. This represents an important information for consumers 
of such products. 
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Background 
The human colon carries about 1010 to 1012 microorganisms per ml gut content. Mostly, these 
are anaerobic bacteria, but also a small number of aerobe and facultative anaerobe bacteria, such as 
Lactobacillae, are detectable. The normal commensal gut flora represents a complex and well 
balanced system of microorganisms that plays a crucial role for the digestion of nutrients, the 
activation and modulation of immune responses as well as for intestinal barrier function and host 
defense [1]. This is supported by observations in patients treated with antibiotics, in whom a disturbed 
commensal flora can frequently be found, often resulting in flatulence and diarrhea [2].  
Since a couple of years, the food industry heavily advertises a new group of products: 
probiotic foods. These probiotic products, available as yoghurts or yoghurt drinks, contain certain 
strains of bacteria. Though the food industry promotes these products in a way that they would 
improve general well being, digestion and even the immune system by modulating the commensal gut 
flora, these possibly beneficial effects have not been proven by scientific data so far. In comparison to 
conventionally available yoghurts or yoghurt drinks, however, these probiotic products are far more 
expensive. They are comprised of diverse bacteria strains, mostly lactobacillae subspecies, what is 
thought to justify the term “probiotic”. 
Specific probiotic products have been established for the treatment of ulcerative colitis (UC), 
such as E.coli Nissle 1917 or VSL#3. The latter contains eight different strains of Lactobacillae and 
Bifidobacteriae. For those products the efficacy for the maintenance of remission in UC patients has 
been proven by a number of clinical trials [3-5]. Interestingly, these probiotics exert antimicrobial 
effects, either via increased production of bactericidal effector proteins, such as human defensins [6; 7] 
or via stimulation of specific immune responses [8]. Further, they increase epithelial barrier function 
[9] and modulate pro-inflammatory responses of the immune system [10]. 
However, the clinically used probotic preparations are produced under controlled conditions 
and contain a similar amount and a high concentration of living, lyophilized bacteria are packed in an 
acid-proof capsule. This ensures quality, safety and availability of the probiotic in the human colon. In 
contrast, probiotic yoghurts contain neither standardized amounts or concentrations of microorganisms 
nor are they lyophilized or kept acid-proof. Therefore, it is unclear whether the amount of 
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microorganisms in these products is even enough to cause beneficial effects in the intestine or, and 
even more important, whether these bacteria are able to survive until they are consumed and whether 
they are still viable after the passage of the stomach acid. These limitations contribute to the fact that 
the role for such advertised probiotics with respect to consumer’s health benefit is still controversial. 
Here, we wanted to address the point whether appropriate storage of probiotic products might 
be essential for the quality and potential effectiveness of these preparations in the human colon. Since 
it is proposed that probiotic yoghurts and yoghurt drinks have to be stored under cool conditions, we 
investigated whether the number of probiotic bacteria in yoghurts is altered by an interruption of the 
cold chain. 
 
 
 
Methods 
Three commonly available probiotic yoghurts from three different manufacturers were 
obtained commercially. Each of the yoghurts contained a different strain of Lactobacillae, one of them 
additionally a strain of Bifidobacteriae. The yoghurts were either kept on 4°C (control yoghurts) or put 
at room temperature (RT) for 6 h or 24 h, respectively, before analysis. RT was considered to be 
continuously 20°C throughout the experiment. From each brand, we tested four different yoghurts at 
each time point. 5 mg of each of the yoghurts were dissolved in 10 ml phosphate buffered saline (PBS) 
and thoroughly mixed. The yoghurt solutions were further diluted (1:10) and 100 µl of each of the 
solutions was applied on Man-Rogosa-Sharpe (MRS) agar plates (Merck, Darmstadt, Germany). MRS 
agar was chosen, since it contains sodium actetate that suppresses the growth of a large number of 
concurrent bacteria and therefore exclusively favours the growth of lactobacillae. Subsequently, agar 
plates containing the yoghurt solutions were incubated at 37 °C for 48 h under aerobe conditions. 
Though lactobacillae originally represent anaerobe bacteria, they are aerotolerant, what means that 
they are also able to live in an oxygen-rich atmosphere. However, lactobacillae do not express the 
enzyme catalase, what catalyzes the reduction of hydrogen peroxide (H2O2) into oxygen and water. 
Therefore we applied 2 µl of H2O2 (Sigma, St. Louis, MO) onto the agar plates to verify that the 
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bacteria growing on these plates are catalase-negative and therefore most likely lactobacillae. To 
quantify the amount of surviving bacteria after exposure to RT and incubation, colony forming units 
(CFU) were counted using a conventional light microscope (Zeiss, Jena, Germany). 
 
 
 
Results 
The first investigated yoghurt (yoghurt 1) contained Lactobacillus johnsonii as a probiotic 
component. Already the visual aspect revealed a clear difference between the yoghurts kept at 4°C and 
the ones that had been exposed to RT. Initially, we evaluated the consistence of the product samples. 
The yoghurts that had been at RT for 6 h and even more the ones kept at RT for 24 h, showed a clear 
separation into two phases: While the lower phase contained the yoghurt part of the product, there was 
also a clear fluid phase on top of the white phase below. Additionally the yoghurts that had been 
exposed to RT were of even more liquid and soft consistence compared to the cooled products. 48 h 
after incubation of the yoghurt dilutions, we then counted the number of CFU on MRS-agar plates. As 
visible in Figure 1A, the agar plates that contained the yoghurt samples that had been kept at 4°C were 
completely covered by CFU of lactobacillae. While the plates containing the yoghurt samples that 
were at RT for 6 h already showed a looser assembly of CFUs, the agar plates with the 24 h samples 
showed only a few CFUs, indicating that only a small number of bacteria was still viable after being 
exposed to RT for 24 h. Statistical analysis revealed that the 6 h plate still contained about 91 % of the 
CFU that were detectable on the control plates (p<0.05; Figure 1B). However, and in accordance to 
the visual aspect, microscopic counting of CFUs on the plate that had been at RT for 24 h, revealed 
that only 44.8 % of the CFU were detectable when compared to control plates (p<0.01). 
 The second analyzed yoghurt product (yoghurt 2) contained the probiotic component 
Lactobacillus GG. Similar to the previous observations, there was a clear separation into a fluid and a 
solid phase in the yoghurts that had been exposed to RT. After incubation, the control plates were full 
of lactobacillae CFUs. However, even after 6 h was a clear difference in the number of CFUs visible 
(Figure 1C). Statistical analysis revealed that after 6 h RT exposure, the number of CFU was 
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decreased by 30 % (p<0.01). After 24 h, this decrease was even further pronounced and only 36.8 % 
of CFUs that were detectable on control plates could be counted by microscopy (p<0.01; Figure 1D). 
The third yoghurt (yoghurt 3) contained Lactobacillus acidophilus and a bifidobacteriae 
subspecies which was not further described. In these products there was also a clear separation 
between a fluid and a solid phase detectable. In addition, the yoghurt mass featured small clumps. 
Here, as visible in representative images in Figure 2A, in the yoghurt samples that had been at RT for 
6 h, only 53.8 % CFU remained (p<0.001) compared to the number of CFU on control plates. 
Interestingly, in the 24 h RT only just about one fourth CFU as compared to the control samples could 
be counted by microscopy (27.1 %; p<0.001; Figure 2B).   
 
 
 
Conclusions 
Our data demonstrate that the number of living probiotic bacteria in yoghurt products 
decreases dramatically when they are exposed to room temperature. Additionally, the decrease in 
living bacteria is dependent on the duration of the RT exposure. This leads to the question, whether, 
already by conventional shopping, the number of probiotic bacteria declines to such an extent that 
there are too less bacteria remaining in the product to be useful. As we have shown, even after 6 h, a 
significant amount of bacteria already had died (in yoghurt three about 50 % of bacteria). Given the 
fact that the cold chain is interrupted for a couple of minutes up to a few hours at any conventional 
shopping, the question arises, whether these probiotic products can show any health benefit for their 
consumers. According to current hypothesis, a certain number of bacteria is needed to cause any 
effects in the GI tract.  However, in contrast to clinically used probiotic compositions, such as E.coli 
Nissle 1917 or VSL#3, the probiotics in the yoghurt are not protected by an acid-proof capsule. 
Therefore, it is high likely that an additional significant number of probiotics does not survive the 
stomach passage and only a slight number of bacteria can arrive finally in the colon. Unfortunately, 
the producers of those probiotic products do not indicate the concentration or amount of bacteria 
within their products. However, Schillinger showed that the majority of probiotic yoghurts contain 
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about 105 viable Lactobacillae per gram yoghurt, when stored continuously in the refrigerator [11]. 
Nevertheless, a direct comparison to clinically used probiotics is impossible. Additionally, each 
bacteria strain induces different effects in vitro as well as in vivo. In contrast to clinically used 
probiotic strains, for most of the commercially advertised bacteria no clinical or basic research data are 
available of the nature of their effects in the human GI tract, neither whether they are beneficial or 
detrimental nor whether they have any effect at all. This clarifies that one must question whether these 
commercial probiotic products will have even any (healthy) effects at all in the human GI tract.  
Taken together, we show that the survival of probiotic bacteria in commercially available 
products is critically dependent on the conditions the products are stored. This might also have a 
strong implication for a putative beneficial effect of the probiotic compositions and, therefore, 
represents important information for the consumers of such probiotic yoghurts. 
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Figure legends 
 
Figure 1. Survival of probiotic bacteria on MRS-agar plates. (A) Representative images of CFU on 
MRS-agar plates (control and 24 h RT) of yoghurt 1 solutions after incubation for 48 h at 37°C and 
(B) statistical analysis of four similar experiments. (C) Representative images of CFU on MRS-agar 
plates (control and 24 h RT) of yoghurt 2 solutions after incubation for 48 h at 37°C and (D) statistical 
analysis of four similar experiments. * indicates p < 0.05, ** = p < 0.01, *** = p < 0.001 vs. control. 
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Figure 2. Survival of probiotic bacteria on MRS-agar plates. (A) Representative images of CFU on 
MRS-agar plates (control and 24 h RT) of yoghurt 3 solutions after incubation for 48 h at 37°C and 
(B) statistical analysis of four similar experiments. *** indicates p < 0.001 vs. control. 
 
 
 
 
 
